ClinicalTrials.gg
RecruitingNCT07275788Updated Mar 17, 2026

A Study of REGEND003 on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)

A Phase 1 interventional study of REGEND003 and Placebo in Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD), sponsored by Regend Therapeutics. Recruiting at 1 site in China. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Regend Therapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 913 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 229 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Planned enrollment
750th of 769
15 · median 192
Started
2026
with 88 others
Phase 1
123 of 913
12 open now
Primary completion
2027-12
later than 158 of 228 live
Registered
796th of 913
by date

Among the 913 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 750th largest by planned enrollment of the 769 interventional ones that give a count, is one of 89 that started in 2026, is one of 123 in phase 1, reaches primary completion later than 158 of the 228 other live ones, and was the 796th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 913 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 913 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

REGEND003, which consists of human kidney progenitor cells, demonstrates promising potential in repairing kidney injury. The purpose of this study is to assess the saftey and tolerability of REGEND003 on patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. It is an exploratory study with multi-centered, randomized, controlled, single-blinded, dose-escalated designs.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)

Keywords

  • Type 2 Diabetes Mellitus
  • Chronic Kidney Disease
  • Cell Therapy
  • Kidney Progenitor Cells
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 30 to 75 years at the time of signing the form;
  • Diagnosed with Type 2 Diabetes Mellitus for at least 1 year;
  • Diagnosed with Chronic Kidney Disease (CKD);
  • Voluntarily sign the informed consent form, be able to cooperate in completing study-related procedures and examinations, capable of adequately recording or describing changes in their condition, and demonstrate strong compliance.

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant, nursing, or planning to be pregnant within a year after using this product (or males whose spouse planning to be pregnant);
  • At the time of screening, subject who is positive in each of treponema pallidum antibody (TP-Ab), (HIV) antibody, surface antigen (HBsAg), virus (HCV) antibody test.

Hepatitis B virus carriers with stable current condition can be enrolled. Cured hepatitis C patients with negative result in HCV ribonucleic acid (RNA) test can be enrolled as well.

  • Presence of a current or prior history of malignant tumor at screening (with the exception of those with disease-free survival for more than 2 years, or deemed to be of low aggressiveness as assessed by the investigator).
  • Patients with Type 1 Diabetes Mellitus;
  • Patients undergoing regular hemodialysis or peritoneal dialysis;
  • Presence of severe acute complications of diabetes or CKD requiring hospitalization within 2 weeks prior to screening;
  • Presence of more than one episode of hypoglycemic coma (blood glucose ≤3.9 mmol/L) within 1 month prior to screening;
  • Patients intolerant to renal puncture/intrarenal injection procedures;
  • Patients with diagnosis of acute kidney injury, congenital or hereditary kidney diseases, renal atrophy, or other renal conditions deemed ineligible by the investigator, as well as patients with a history of kidney transplantation at screening;
  • Presence of severe systemic diseases within 6 months prior to screening and judged by the investigator as unsuitable for the study;
  • Patients requiring long-term anticoagulant or antiplatelet therapy who, in the investigator's judgment, cannot discontinue medication 1 week prior to renal puncture/intrarenal injection procedures;
  • Patients with suicidal risk, history of psychiatric disorders, or history of epilepsy at screening;
  • Patients with severe arrhythmias or heart conduction disorders (degree II or above) in 12-lead test at screening;
  • Patients participated in other clinical trials with interventions within 1 month prior to screening;
  • Subject with assessed survival time of less than 1 year by investigators at screening;
  • Investigators, co-investigators, study coordinators, employees of participating investigators or research centers, or family members of the above individuals;
  • Any condition that, in the investigator's judgment, may increase subject risk or interfere with the clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    REGEND003

    REGEND003 for dosage escalation

    Biological: REGEND003

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • BiologicalREGEND003

    REGEND003

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Adverse Event (AE) associated with the Cell Therapy

    The incidence and severity of adverse events will be evaluated.

    Time frame: Within 24 weeks post-treatment

Secondary outcomes

  1. Complications associated with Intrarenal Injection

    The incidence will be evaluated.

    Time frame: Within 24 weeks post-treatment

  2. Change from Baseline in Concentration of C-Reactive Protein

    C-Reactive Protein is a marker of inflammation in the body.

    Time frame: Within 24 weeks post-treatment

  3. Change from Baseline in Glomerular Filtration Rate (GFR)

    GFR is a critical measurement of kidney function, reflecting how efficiently the kidneys filter blood

    Time frame: Within 24 weeks post-treatment

  4. Change from Baseline in Concentration of Serum Creatinine

    A creatinine test is a measure of how well the kidneys are doing their job of filtering waste from the blood.

    Time frame: Within 24 weeks post-treatment

  5. Change from Baseline in 24-Hour Urinary Protein Excretion

    A 24-hour urine protein test measures the amount of albumin (the most common protein filtered in the kidney) in the urine over 24 hours.

    Time frame: Within 24 weeks post-treatment

  6. Change from Baseline in Urine Albumin-Creatinine Ratio (uACR)

    A urine albumin-creatinine ratio (uACR) is a urine (pee) test that help to understand the overall kidney health. A high uACR may be a sign of kidney disease.

    Time frame: Within 24 weeks post-treatment

  7. Change from Baseline in Kidney Volume

    Kidney volume provides key insights in many clinical situations. Abnormal kidney volumes often signal problems.

    Time frame: Winthin 24 weeks post-treatment

  8. Change from Baseline in Renal Cortical Thickness (RCT)

    RCT has also been used in the diagnosis of chronic kidney disease. With the progression of the disease, RCT decreases.

    Time frame: Within 24 weeks post-treatment

  9. Changes from Baseline in the Outcomes from Kidney Disease Quality of Life (KDQOL) Survey

    The Kidney Disease Quality of Life (KDQOL) survey has long been used to assess the burden, symptoms/problems, and effects of kidney disease on a patient's quality of life. The minimal value is 0 and the maximal value is 100. A higher score means a better outcome.

    Time frame: Within 24 weeks post-treatment

  10. Change from Baseline in Blood Pressure

    Both systolic and diastolic blood pressures are assessed.

    Time frame: Within 24 weeks post-treatment

  11. Time from Injection to First Kidney Disease Progression (KDP)

    KDP is assessed by stage of disease, mortality and continous decreasing of GFR.

    Time frame: Within 24 weekd post-treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 23 months is above that.

Counting every sponsor, half of 517 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 10, 2025
StartActual
Jan 8, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07275788
Lead sponsor
Regend Therapeutics
Collaborators
Shanghai Tongji Hospital, Tongji University School of Medicine
Responsible party
Sponsor
First posted
Dec 10, 2025
Start date
Jan 8, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 17, 2026

Study contacts

Prof. Yu
Contact
yuchen@tongji.edu.cn
086-021-66111062

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion